Introduction
The late Dr Arthur Morris (1889 Morris ( -1980 was appointed Medical Superintendant of St Leonard's Hospital, Shoreditch in 1935, and developed a lifelong interest in James Parkinson, who had been a parish doctor to the workhouse which stood on the site of St Leonard's Hospital. The idea of a biography led him to become an avid collector of his life and times. He became an informed historian on London in 1800, Parkinson's descendants, palaeontology, politics and the pop-gun plot, and absolutely anything connected with Parkinson. He died before the biography was completed but it has at last been published. This was due to the determination and dedication of his widow, Dorothy Morris. The result is a classic of our times, and an overdue tribute to our national medical hero, James Parkinson 
Pathophysiology
The melanin-containing cells of the substantia nigra terminate in the caudate nucleus and putamen. Dopamine was found to be a neurotransmitter and its lack was noted to cause akinesia and rigidity. Levodopa revolutionized both our understanding and the management of Parkinson's disease in the 1960s. In 1979 another biochemical milestone was noted in Californian drug abusers who developed a form of Parkinson's disease due to an illicit pethidine derivative, methyl phenyl tetrahydropyridine (MPTP) which is specific to the nigrostriatum.3 It causes biochemical changes within mitochrondria where it inhibits the enzymic respiratory chain. The biochemical process also leads to the generation of highly reactive free radicals which oxidize cellular lipids and cause extensive cell death in the nigrostriatum. Tocopherol is a scavenger of free radicals and may avert these catastropic biochemical changes.
Treatment (Table I with a peripheral decarboxylase inhibitor which allows a smaller dose, prevents its wasteful peripheral metabolism and thereby fewer side effects. Nausea is minimized by its administration after food in a ratio of 1:4 peripheral decarboxylase inhibitor: levodopa. The two commonly used inhibitors are carbidopa and benserazide. The 'on-off syndrome describes the all-or-none clinical response and its management relies on improved delivery of L-dopa to the brain by oral sustained-release preparations, subcutaneous infusions of such dopamine agonists as lisuride and apomorphine or transdermal delivery.5
Bromocriptine
Bromocriptine is a dopamine agonist used in acromegaly and for neutralizing prolactin secretion. It has been administered in low dosage in combination with levodopa to prolong the benefits ofthe latter.6 However, its adverse effects may force it to be discontinued. Selegiline (Deprenyl; Eldepryl) Monoamine oxidase breaks down dopamine so it was rational to try monoamine oxidase inhibitors to prevent the dopamine deficit; and in practice to allow a reduction in levodopa dosage. A controlled trial suggests that selegiline, given with tocopherol anti-oxidative therapy, slows the development of disability by approximately one year; it slows disease progression and may reduce the rate of neuronal degeneration.7'8 It is recommended in a dose of 5 to 10 mg daily in the earliest stage of the disease, together with tocopherol to offset damaging superoxides and peroxides.
Unlike other monoamine oxidase inhibitors, it can be safely used with levodopa. Side effects are rare, but it should be avoided in patients with peptic ulceration. Amantadine This drug was originally introduced as prophylaxis for influenza A virus infection, and by serendipity it was noted to be useful in a woman with Parkinson's disease, causing remission of rigidity, tremor and akinesia. When the drug was discontinued, she experienced a relapse.9 It is often used in the early stage of the disease. It is likely that it stimulates the release of dopamine.
Surgery
Leslie Oliver'0 was an early enthusiast for stereotactic surgery. Serendipity led to the interesting observation that the tremor and rigidity of Parkinson's disease disappeared after accidental tearing ofthe anterior choroidal artery. " It was due to infarction of the substantia nigra and medial part of the globus pallidus. Transplantation"5 of adrenal medulla or human fetal mesencephalic tissue remains an experimental procedure. The most promising results of surgery have followed fetal mesencephalic grafts into the putamen where dopamine deficiency is most severe. The present clear message is to use fetal grafts rather than adrenal autografts, and into the putamen rather than the caudate nucleus.'2"3 All techniques will surely provide data and a better understanding of a disorder which Parkinson described so accurately 173 years ago.
Management
Once the clinical diagnosis is established with confidence, consider the following lines ofmanagement:
1. Selegiline is indicated at the earliest stage of the disease. Clinical trials indicate that it will delay the development of disability by approximately one year and it also slows disease progression.7 '8 Tocopherol should also be given as a free radical scavenger.
2. The disabled patient should be given the benefit of levodopa together with benserazide or carbidopa (Madopar or Sinemet). 3. Amantadine is weakly dopaminergic and offers slight additional benefit. Consider it particularly during the influenza season for it protects against influenza A. 4. Bromocriptine is dopaminergic and combines well with levodopa in the patient who suffers fluctuations of response with levodopa alone. This combination serves to minimize 'on-off' attacks. 5. Anticholinergic drugs combine well with levodopa in reducing salivation and dribbling, tremor and rigidity. Their side effects of dry mouth, constipation, blurring of vision and hesitancy ofmicturition may prove unacceptable to the patient. They are contraindicated in patients with prostatism and glaucoma. 6. Neurosurgery remains a promising but still experimental procedure. Stereotactic procedures are used to implant fetal mesencephalic tissue into the putamen. Surely this experimental work will provide an answer during this decade.'2"13"14 
